Silver Book Fact

A prostate cancer vaccine, sipleucel-T immunotherapy, in men with metastatic castration-resistant prostate
cancer, reduced the risk of death by 22 percent compared to placebo, and represented a 4.2 month improvement in median survival.

Kantoff, P, C Higano, N Shore, E Berger, E Small, D Penson, et al. Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer. NEJM. 2010; 363: 411-22. http://www.nejm.org/doi/full/10.1056/NEJMoa1001294

Reference

Title
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Publication
NEJM
Publication Date
2010
Authors
Kantoff, P, C Higano, N Shore, E Berger, E Small, D Penson, et al.
Pages
411-22
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • In the U.S., new cancer drugs have increased life expectancy at birth by 10.7%.  
  • When detected early, the 5-year survival rate for colorectal cancer is 90%; however, only 39% of colorectal cancers are diagnosed early, mainly because of low rates of screening.  
  • Medicines in Development for Cancer  
  • Since 1975, the five year survival rate for breast cancer patients has increased by 40 percent.  
  • Cancer death rates for all races/ethnicities and both sexes combined decreased by 2.1% per year from 2002-2004, nearly twice the annual decrease of 1.1% per year from 1993-2002.